Earnings summaries and quarterly performance for Rallybio.
Executive leadership at Rallybio.
Board of directors at Rallybio.
CA
Christine A. Nash, M.B.A.
Detailed
Director
HM
Helen M. Boudreau, M.B.A.
Detailed
Director
HL
Hui Liu, Ph.D., M.B.A.
Detailed
Director
LI
Lucian Iancovici, M.D.
Detailed
Director
MW
Martin W. Mackay, Ph.D.
Detailed
Chairman
PS
Paula Soteropoulos
Detailed
Lead Director
RH
Robert Hopfner, R.Ph., Ph.D., M.B.A.
Detailed
Director
RH
Ronald Hunt, M.B.A.
Detailed
Director
WK
Wendy K. Chung, M.D., Ph.D.
Detailed
Director
Research analysts covering Rallybio.
Recent press releases and 8-K filings for RLYB.
Rallybio Stockholders Approve Reverse Stock Split
RLYB
Proxy Vote Outcomes
Delisting/Listing Issues
- Rallybio Corporation held a special meeting of stockholders on January 26th, 2026, with approximately 82.81% of the voting power present, establishing a quorum.
- Stockholders voted in favor of approving an amendment to the Certificate of Incorporation to effect a reverse stock split.
- The approved reverse stock split ratio will range from 1:5 shares up to 1:20 shares, with the specific ratio to be selected by the Board of Directors.
- Final voting results will be reported in a Form 8-K within four business days.
9 hours ago
Rallybio Stockholders Approve Reverse Stock Split Proposal
RLYB
Proxy Vote Outcomes
- Rallybio Corporation held its 2026 Special Meeting of Stockholders on January 26, 2026, with approximately 82.81% of the voting power represented, establishing a quorum.
- Stockholders voted on Proposal One to approve an amendment for a reverse stock split of common stock at a ratio ranging from 1-for-5 up to 1-for-20 shares, with the specific ratio to be selected by the Board of Directors.
- A preliminary voting report indicated that a majority of the shares outstanding and entitled to vote were in favor of approving the reverse stock split.
- The final results of the vote will be reported in a Form 8-K within four business days.
10 hours ago
Rallybio Stockholders Approve Reverse Stock Split Proposal
RLYB
Proxy Vote Outcomes
Delisting/Listing Issues
- Rallybio Corporation's stockholders approved a proposal for a reverse stock split at a special meeting held on January 26, 2026.
- The approved ratio for the reverse stock split will range from 1-for-5 to 1-for-20 shares, with the specific ratio to be determined by the Board of Directors.
- A quorum was present at the meeting, representing approximately 82.81% of the voting power as of the December 30, 2025 record date.
- The final voting results will be reported in a Form 8-K within four business days.
10 hours ago
Rallybio Reports Third Quarter 2025 Financial Results and Business Updates
RLYB
Earnings
New Projects/Investments
Guidance Update
- Rallybio reported net income of $16.0 million, or $0.36 per common share, for the third quarter ended September 30, 2025.
- Revenue for the third quarter of 2025 was $0.2 million.
- The company generated $20 million from the sale of its interest in REV102, extending its cash runway through 2027. As of September 30, 2025, cash, cash equivalents, and marketable securities were $59.3 million.
- Dosing of Cohort 1 in the RLYB116 Phase 1 confirmatory PK/PD clinical trial was completed in September 2025, with data expected in the fourth quarter of 2025.
Nov 6, 2025, 1:12 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more